Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a buy rating for Krystal Biotech (KRYS) with a target price of $240.00, indicating a potential upside of 64.72% from its current price.
• Despite adjustments from other analysts, Krystal Biotech has a consensus rating of Buy from analysts, with an average price target of $210.75.
• The company reported earnings per share (EPS) of $1.29 for the last quarter, surpassing expectations and highlighting a strong net margin of 40.85%.

HC Wainwright reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has a $240.00 target price on the stock.

Several other equities research analysts have also recently commented on KRYS. Citigroup reissued a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Tuesday, August 5th. Guggenheim reduced their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Bank of America reduced their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Down 0.4%

Shares of KRYS stock traded down $0.57 during trading hours on Friday, reaching $146.31. 38,171 shares of the company's stock were exchanged, compared to its average volume of 328,551. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The stock has a market capitalization of $4.23 billion, a P/E ratio of 29.68 and a beta of 0.70. The business has a fifty day moving average price of $144.84 and a 200-day moving average price of $154.39.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. Brooklyn Investment Group grew its stake in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after buying an additional 105 shares during the last quarter. Hantz Financial Services Inc. grew its stake in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after buying an additional 179 shares during the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the first quarter worth approximately $29,000. Fifth Third Bancorp increased its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the period. Finally, First Horizon Advisors Inc. increased its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock worth $34,000 after purchasing an additional 166 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).